BioActor acquires Arabinoxylan-assets from DF3-WITAXOS and obtains positive EFSA opinion for its Arabinoxylan ingredient
Press release
BioActor has acquired patents, know-how and clinical data relating to short-chain wheat arabinoxylans from DF3-WITAXOS. BioActor’s arabinoxylan ingredient obtained positive EFSA opinion for glycaemic control.
Arabinoxylan extract from wheat endosperm
BioActor BV announced today that it has acquired certain patents, manufacturing know-how and clinical data from DF3-WITAXOS. Moreover, DF3-WITAXOS’ managing director, Yann Dugenet, has joined BioActor as Director Product Development.
BioActor has already a long-chain Arabinoxylan ingredient derived from wheat endosperm in its portfolio, Naxus®, which recently obtained a positive EFSA Opinion for glycaemic control, and for which promising scientific evidence was recently obtained towards other health endpoints. Hans van der Saag, BioActor’s managing director comments; “The addition of short-chain Arabinoxylans which are derived from the same raw material source as our long chain Arabinoxylans-ingredient, further strengthens our portfolio of patented speciality fibers with clinically proven health effects”.
DF3 WITAXOS obtained excellent clinical data on prebiotic effects of its short-chain Arabinoxylans in a collaborative clinical trial with Institut Pasteur in Lille. Those results were consistent with earlier positive results from in-vitro experiments and in vivo tests on animal models. The integration of this ingredient in the Naxus® range of Arabinoxylan speciality fibers will allow for economies of scale in manufacturing and offers customers more choice in application possibilities.
EFSA has issued a positive opinion for a health claim on glycaemic control in connection with arabinoxylans produced from the wheat endosperm. EFSA proposes the following wording for the health claim: “Consumption of arabinoxylan contributes to a reduction of the glucose rise after a meal”. Naxus® is wheat endosperm derived arabinoxylan, which has been tested in several human studies and directly benefits from this health claim.
Naxus® is also being studied for immune modulation in the context of a 6 million Euro European research project – FIBEBIOTICS –, which is coordinated by Wageningen University (www.fibebiotics.eu).
About BioActor
BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.
Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
Further information can be found on: www.naxus.nl
